Hepion Pharmaceuticals acquires ctRNA biomarker assay to detect liver cancer early, with possible applications for other solid tumors.

A cutting-edge non-invasive diagnostic platform for solid tumor types, including liver cancer, has the potential for applications in a wide range of other tumors. This next-generation platform is poised to revolutionize diagnostics with its innovative approach. It offers a promising alternative for patients, with the potential to improve detection rates and treatment outcomes. This advancement signifies a significant leap forward in the medical field, with the ability to impact numerous individuals affected by various types of solid tumors.